UBR7 and breast cancer: Nomura’s team found that a manumycin polyketide, asukamycin (Table 11), has multiple electrophilic sites, targets Cys374 of the E3 ligase UBR7 in breast cancer cells, and participates in the molecular glue interaction of the new substrate tumor suppressor TP53 in order to form a UBR7-asukamycin-TP53 complex to exert anticancer effects (Table 12).